Nectar Lifesciences Limited
: NECLIFE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Nectar Lifesciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Nectar Lifesciences Ltd is a research-driven pharmaceutical company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage forms. The company maintains a strong focus on anti-infectives, particularly Cephalosporins, while also operating as a Contract Manufacturing Organisation (CMO) for global pharmaceutical innovators.
Business Model
The company generates revenue through the large-scale production and sale of APIs and finished formulations, alongside providing contract manufacturing services to international pharmaceutical clients.
Growth Outlook
Growth is primarily driven by the company's established position in the anti-infective segment and its ability to leverage its manufacturing infrastructure to support global pharmaceutical innovators through CMO partnerships.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality standards and inspections by global health authorities, where non-compliance could lead to export restrictions.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and intermediates can significantly impact the company's operating margins.
- Foreign Exchange Risk. As a participant in global markets, the company is exposed to currency fluctuations that may affect the profitability of its export-oriented business.
- Sector Competition. The pharmaceutical industry is highly competitive, with pricing pressures from generic manufacturers potentially impacting market share and profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Nectar Lifesciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹286 Cr
TTM · consolidated
NET PROFIT
₹-293 Cr
TTM · consolidated
EPS
₹-1.66
TTM · consolidated
RETURN ON EQUITY
-34.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-4.7%
TTM · consolidated
P/E
-6.6x
Q4 FY26 · consolidated
EV/EBITDA
-1.8x
Q4 FY26 · consolidated
EBITDA MARGIN
-39.9%
TTM · consolidated
NET PROFIT MARGIN
-3520.2%
Q2 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Nectar Lifesciences LimitedNECLIFE | ₹242 Cr | -7.51 | -2.12 | -82.9% | -39.9% | -34.0% | -4.7% | -12.6% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Nectar Lifesciences Limited
: NECLIFE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Nectar Lifesciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Nectar Lifesciences Ltd is a research-driven pharmaceutical company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage forms. The company maintains a strong focus on anti-infectives, particularly Cephalosporins, while also operating as a Contract Manufacturing Organisation (CMO) for global pharmaceutical innovators.
Business Model
The company generates revenue through the large-scale production and sale of APIs and finished formulations, alongside providing contract manufacturing services to international pharmaceutical clients.
Growth Outlook
Growth is primarily driven by the company's established position in the anti-infective segment and its ability to leverage its manufacturing infrastructure to support global pharmaceutical innovators through CMO partnerships.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality standards and inspections by global health authorities, where non-compliance could lead to export restrictions.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and intermediates can significantly impact the company's operating margins.
- Foreign Exchange Risk. As a participant in global markets, the company is exposed to currency fluctuations that may affect the profitability of its export-oriented business.
- Sector Competition. The pharmaceutical industry is highly competitive, with pricing pressures from generic manufacturers potentially impacting market share and profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Nectar Lifesciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹286 Cr
TTM · consolidated
NET PROFIT
₹-293 Cr
TTM · consolidated
EPS
₹-1.66
TTM · consolidated
RETURN ON EQUITY
-34.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-4.7%
TTM · consolidated
P/E
-6.6x
Q4 FY26 · consolidated
EV/EBITDA
-1.8x
Q4 FY26 · consolidated
EBITDA MARGIN
-39.9%
TTM · consolidated
NET PROFIT MARGIN
-3520.2%
Q2 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26